CINNARIZINE

Cinnarizine is a calcium channel blocker used for vertigo and motion sickness. Side effects include drowsiness, weight gain, and dry mouth.

SKU: 787bb839edbf Category: Tag:

Product Description


Mechanism of Action

Cinnarizine is a calcium‑channel blocker with antihistaminic (H₁) and anti‑vertigo properties. It inhibits L‑type calcium channels, reducing smooth‑muscle contractility, while its H₁‑antagonism suppresses vestibular nuclei excitability—useful in motion‑sickness research. It also improves microcirculation by reducing blood viscosity.

Benefits and Advantages

Used in vestibular‑function studies, motion‑sickness modelling, calcium‑channel pharmacology, cerebral‑perfusion research and combined antihistamine–vasodilator SAR investigations.

Side Effects and Risks

Risks include sedation, weight gain, extrapyramidal symptoms (rare), dry mouth and hypotension. Handle with CNS‑active calcium‑antagonist precautions.

Datasheet


Molecular Formula

C26H28N2

Molecular Weight

368.5 g/mol

CAS Number

298-57-7

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

1.72e-03 g/L

Purity

Purity information is available upon request (COA).

Synonym

cinnarizine; 298-57-7; Stugeron; Dimitron; Folcodal

IUPAC/Chemical Name

1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine

InChl Key

DERZBLKQOCDDDZ-JLHYYAGUSA-N

InChl Code

InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+

References

https://pubchem.ncbi.nlm.nih.gov/compound/1547484;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download